# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>S.No.</th>
<th>CONTENTS</th>
<th>PAGE NO.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Introduction</td>
<td>1 – 12</td>
</tr>
<tr>
<td>2.</td>
<td>Review of Literature</td>
<td>13 – 54</td>
</tr>
<tr>
<td>3.</td>
<td>Aims and Objectives</td>
<td>55</td>
</tr>
<tr>
<td>4.</td>
<td>Materials and Methods</td>
<td>56 – 94</td>
</tr>
<tr>
<td>5.</td>
<td>Results and Observations</td>
<td>95 – 149</td>
</tr>
<tr>
<td>6.</td>
<td>Discussion</td>
<td>150 – 165</td>
</tr>
<tr>
<td>7.</td>
<td>Summary and Conclusion</td>
<td>166 – 172</td>
</tr>
<tr>
<td>8.</td>
<td>Bibliography</td>
<td>173 – 211</td>
</tr>
<tr>
<td>9.</td>
<td>Master Charts</td>
<td>212 – 215</td>
</tr>
<tr>
<td>•</td>
<td>Appendices</td>
<td></td>
</tr>
</tbody>
</table>
LIST OF TABLES

Table 1. Factors regulating the secretion of adiponectin.

Table 2. Showing age of obese and non obese type 2 diabetic subjects.

Table 3. Showing serum total cholesterol levels amongst obese and non obese type 2 diabetic subjects.

Table 4. Showing serum triglyceride levels amongst obese and non obese type 2 diabetic subjects.

Table 5. Showing serum high density lipoprotein-cholesterol (HDL-C) levels amongst obese and non obese type 2 diabetic subjects.

Table 6. Showing serum low density lipoprotein-cholesterol (LDL-C) levels amongst obese and non obese type 2 diabetic subjects.

Table 7. Showing serum very low density lipoprotein-cholesterol (VLDL-C) levels amongst obese and non obese type 2 diabetic subjects.

Table 8. Showing age of obese and non obese non-diabetic subjects.

Table 9. Showing serum total cholesterol levels amongst obese and non obese non-diabetic subjects.

Table 10. Showing serum triglyceride levels amongst obese and non obese non-diabetic subjects.

Table 11. Showing serum high density lipoprotein-cholesterol (HDL-C) levels amongst obese and non obese non-diabetic subjects.
Table 12. Showing serum low density lipoprotein-cholesterol (LDL-C) levels amongst obese and non obese non-diabetic subjects.

Table 13. Showing serum very low density lipoprotein-cholesterol (VLDL-C) levels amongst obese and non obese non-diabetic subjects.

Table 14. Showing variations in age amongst different subjects under study.

Table 15. Showing variations in serum leptin levels amongst male and female subjects under study.

Table 16. Showing variations in serum adiponectin levels amongst male and female subjects under study.

Table 17. Showing variations in high density lipoprotein-cholesterol (HDL-C) levels amongst male and female subjects under study.

Table 18. Showing variations in fasting plasma glucose (FPG) levels amongst different subjects under study.

Table 19. Showing variations in plasma insulin levels amongst different subjects under study.

Table 20. Showing variations in serum C-peptide levels amongst different subjects under study.

Table 21. Showing variations in serum leptin levels amongst different subjects under study.

Table 22. Showing variations in serum adiponectin levels amongst different subjects under study.
Table 23. Showing variations in serum total cholesterol levels amongst different subjects under study.

Table 24. Showing variations in serum triglyceride levels amongst different subjects under study.

Table 25. Showing variations in serum high density lipoprotein-cholesterol (HDL-C) levels amongst different subjects under study.

Table 26. Showing variations in serum low density lipoprotein-cholesterol (LDL-C) levels amongst different subjects under study.

Table 27. Showing variations in serum very low density lipoprotein-cholesterol (VLDL-C) levels amongst different subjects under study.

Table 28. Showing variations in insulin resistance (calculated by Homeostasis Model Assessment Method) amongst different subjects under study.
LIST OF FIGURES

Figure 1. Showing estimated number of diabetic subjects in India.

Figure 2. Showing Glycemic Continuum and Cardiovascular Disease.

Figure 3. Showing Hyperglycemia, Insulin Resistance and Cardiovascular Disease.

Figure 4. Showing a) Projected prevalence of overweight males in India aged 30 years or more, 2005 and 2015.

       b) Projected prevalence of overweight females in India aged 30 years or more, 2005 and 2015.

Figure 5. Showing adipocytokines produced by adipose tissue.

Figure 6. Showing adipocyte dysfunction and insulin resistance.

Figure 7. Showing a) Metabolic effects of adiponectin.

       b) Adiponectin signalling in liver, skeletal muscle and hypothalamus.

Figure 8. Showing inflammation and insulin resistance in adipose tissue.

Figure 9. Showing leptin, hypothalamus and energy homeostasis.
Figure 10. Showing interrelationship between adipose tissue and the pancreatic β-cell: the ‘adipo-insular axis’.

Figure 11. Showing a) Synthesis of insulin from preproinsulin.

b) Structure of insulin.

Figure 12. Showing regulation of insulin secretion from pancreatic beta cell.

Figure 13. Showing anti-inflammatory and anti-apoptotic effects of C-peptide.

Figure 14. Showing calculation of Body Mass Index (BMI).

Figure 15. Showing calibration curve of insulin.

Figure 16. Showing calibration curve of C-peptide.

Figure 17. Showing calibration curve of adiponectin.

Figure 18. Showing calibration curve of leptin.

Figure 19. Showing body mass index (BMI) amongst obese and non obese type 2 diabetic subjects.

Figure 20. Showing fasting plasma glucose (FPG) levels amongst obese and non obese type 2 diabetic subjects.
Figure 21. Showing plasma insulin levels amongst obese and non obese type 2 diabetic subjects.

Figure 22. Showing serum C-peptide levels amongst obese and non obese type 2 diabetic subjects.

Figure 23. Showing serum leptin levels amongst obese and non obese type 2 diabetic subjects.

Figure 24. Showing serum adiponectin levels amongst obese and non obese type 2 diabetic subjects.

Figure 25. Showing insulin resistance (calculated by Homeostasis Model Assessment Method) amongst obese and non obese type 2 diabetic subjects.

Figure 26. Showing body mass index (BMI) amongst obese and non obese non-diabetic subjects.

Figure 27. Showing fasting plasma glucose (FPG) levels amongst obese and non obese non-diabetic subjects.

Figure 28. Showing plasma insulin levels amongst obese and non obese non-diabetic subjects.
Figure 29. Showing serum C-peptide levels amongst obese and non obese non-diabetic subjects.

Figure 30. Showing serum leptin levels amongst obese and non obese non-diabetic subjects.

Figure 31. Showing serum adiponectin levels amongst obese and non obese non-diabetic subjects.

Figure 32. Showing insulin resistance (calculated by Homeostasis Model Assessment Method) amongst obese and non obese non-diabetic subjects.

Figure 33. Showing correlation between serum total cholesterol and high density lipoprotein-cholesterol (HDL-C) levels.

Figure 34. Showing correlation between serum total cholesterol and low density lipoprotein-cholesterol (LDL-C) levels.

Figure 35. Showing correlation between serum total cholesterol and very low density lipoprotein-cholesterol (VLDL-C) levels.

Figure 36. Showing correlation between serum triglycerides and very low density lipoprotein-cholesterol (VLDL-C) levels.
Figure 37. Showing correlation between plasma insulin levels and insulin resistance (calculated using Homeostasis Model Assessment Method).

Figure 38. Showing biochemical aspects and pharmacologic targets of Diabesity.